CD8A and metastatic malignant neoplasm in the lymph nodes: The 5‐year OS rate of the CD8+/PD‐L1 TC− group patients was up to 84.9%, whereas it was only 24.1% in the CD8−/PD‐L1 TC+ group; lymph node metastasis was significantly higher in this group compared with the other three subgroups.